Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Cancer Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

1 month–12 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients between the ages of 1-12 month,
ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study

Exclusion criteria

younger than 1month or older than 12 months.
hepatic or renal failure
A history of allergy to study medication

Treatment and study plan

Sugammadex

Drug

Other names: Bridion

Primary outcomes

The efficacy of sugammadex were assessed by using Train of four (TOF)

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Baskent University

Other

Registry information

Official study title

Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2016
First posted: Mar 15, 2016
Registry last updated: Mar 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed